Novel anion exchange membrane chromatography method for the separation of empty and full adeno-associated virus.
adeno-associated virus
empty particles
gene therapy
membrane chromatography
step gradient elution
Journal
Biotechnology journal
ISSN: 1860-7314
Titre abrégé: Biotechnol J
Pays: Germany
ID NLM: 101265833
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
revised:
02
11
2021
received:
27
04
2021
accepted:
05
11
2021
pubmed:
19
12
2021
medline:
10
2
2022
entrez:
18
12
2021
Statut:
ppublish
Résumé
A challenge in the production of recombinant Adeno-Associated Virus (AAV) for gene therapies is the presence of capsids that lack the required gene of interest. The impact of these empty vectors in therapies is not fully understood, however the ability to control the ratio of empty to full particles, which contain the genetic payload, is a necessary step in the purification of these viruses. In this study, a novel anion exchange chromatography elution method for enrichment of full AAV particles is demonstrated. A step gradient with small conductivity increases of around 1 mS cm
Identifiants
pubmed: 34921599
doi: 10.1002/biot.202100219
doi:
Substances chimiques
Anions
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2100219Informations de copyright
© 2021 The Authors. Biotechnology Journal published by Wiley-VCH GmbH.
Références
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., Cross, D., Marshall, K. A., Walshire, J., Kehoe, T. L., Reichert, H.,, Davis, M., Raffini, L., George, L. A., Hudson, F. P., … Maquire, A. M. (2017). Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: A randomised, controlled, open-label, phase 3 trial. Lancet, 390, 849-860.
Samaranch, L., Pérez-Cañamás, A., Soto-Huelin, B., Sudhakar, V., Jurado-Arjona, J., Hadaczek, P., Ávila, J., Bringas, J. R., Casas, J., Chen, H., He, X., Schuchman, E. H., Cheng, S. H., Forsayeth, J., Bankiewicz, K. S., & Ledesma, M. D. (2019). Adeno-associated viral vector serotype 9-based gene therapy for Niemann-Pick disease type A. Science Translational Medicine, 11, 3738.
Hampson, D. R., Hooper, A. W. M., & Niibori, Y. (2019). The application of adeno-associated viral vector gene therapy to the treatment of fragile X syndrome. Brain Science, 9, 32.
Wu, Z., Asokan, A., & Samulski, R. J. (2006). Adeno-associated virus serotypes: Vector toolkit for human gene therapy. Molecular Therapy, 14, 316-327.
Ling, C., Wang, Y., Lu, Y., Wang, L., Jayandharan, G. R., Aslanidi, G. V., Li, B., Cheng, B., Ma, W., Lentz, T., Ling, C., Xiao, X., Samulski, R J., Muzyczka, N., & Srivastava, A. (2015). The adeno-associated virus genome packaging puzzle. Journal of Molecular and Genetic Medicine, 9, 175
Qu, G., Bahr-Davidson, J., Prado, J., Tai, A., Cataniag, F., McDonnell, J., Zhou, J., Hauck, B., Luna, J., Sommer, J. M., Smith, P., Zhou, S., Colosi, P., High, K. A., Pierce, G. F., & Wright, J. F. (2007). Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography. Journal of Virological Methods, 140(1-2), 183-192.
Gao, K., Li, M., Zhong, L., Su, Q., Li, J., Li, S., He, R., Zhang, Y., Hendricks, G., Wang, J., & Gao, G. (2014). Empty virions in AAV8 vector preparations reduce transduction efficiency and may cause total viral particle dose-limiting side-effects. Molecular Therapy - Methods & Clinical Development, 1, 20139.
Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., Howard, C., Tai, A., Podsakoff, G. M., Zhou, S., Basner-Tschakarjan, E., Wright, J. F., & High, K. A. (2013). Overcoming preexisting humoral immunity to AAV using capsid decoys. Science Translational Medicine, 5, 194ra92.
Wang, Q., Dong, B., Pokiniewski, K. A., Firrman, J., wu, Z., Chin, M. P. S., Chen, X., Liu, L., Xu, R., Diao, Y., & Xiao, W. (2017). Syngeneic AAV pseudo-particles potentiate gene transduction of AAV vectors. Molecular Therapy - Methods & Clinical Development, 4, 149-158.
Burnham, B., Nass, S., Kong, E., Mattingly, M., Woodcock, D., Song, A., Wadsworth, S., Cheng, S. H., Scaria, A., & O'Riordan, C. R. (2015). Analytical ultracentrifugation as an approach to characterize recombinant adeno-associated viral vectors. Hum Gene Therapy: Methods, 26, 228.
Hermens, W. T. J. M. C., Brake, O. T., Dijkhuizen, P. A., Sonnemans, M. A. F., Grimm, D., Kleinschmidt, J. A., & Verhaagen, J. (1999). Purification of recombinant adeno-associated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system. Human Gene Therapy, 10, 1885.
Okada, T., Nonaka-Sarukawa, M., Uchibori, R., Kinoshita, K., Hayashita-Kinoh, H., Nitahara-Kasahara, Y., Takeda, S. i., & Ozawa, K. (2009). Scalable purification of adeno-associated virus serotype 1 (AAV1) and AAV8 vectors, using dual ion-exchange adsorptive membranes. Human Gene Therapy, 20, 1013.
Tomono, T., Hirai, Y., Okada, H., Adachi, K., Ishii, A., Shimada, T., Onodera, M., Tamaoka, A., & Okada, T. (2016). Ultracentrifugation-free chromatography-mediated large-scale purification of recombinant adeno-associated virus serotype 1 (rAAV1). Molecular Therapy - Methods & Clinical Development, 3, 15058.
Kaludov, N., Handelman, B., & Chiorini, J. A. (2002). Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography. Human Gene Therapy, 13, 1235.
Potter, M., Lins, B., Mietzsch, M., Heilbronn, R., Vliet, K. V., Chipman, P., Agbandje-McKenna, M., Cleaver, B. D., Clément, N., Byrne, B. J., & Zolotukhin, S. (2014). A simplified purification protocol for recombinant adeno-associated virus vectors. Molecular Therapy - Methods & Clinical Development, 1, 14034.
Grieger, J. C., Soltys, S. M., & Samulski, R. J. (2016). Production of recombinant adeno-associated virus vectors using suspension HEK293 cells and continuous harvest of vector from the culture media for GMP FIX and FLT1 clinical vector. Molecular Therapy, 24(2), 287-297.
Nass, S. A., Mattingly, M. A., Woodcock, D. A., Burnham, B. L., Ardinger, J. A., Osmond, S. E., Frederick, A. M., Scaria, A., Cheng, S. H., & O'Riordan, C. R. (2017). Universal method for the purification of recombinant AAV vectors of differing serotypes. Molecular Therapy - Methods & Clinical Development, 9, 33-46.
Wang, C., Mulagapati, S. H. R., Chen, Z., JingDu, X. Z., Xi, G., Chen, L., Linke, T., Gao, C., Schmelzer, A E., & Liu, D. (2019). Developing an anion exchange chromatography assay for determining empty and full capsid contents in AAV6.2. Molecular Therapy - Methods & Clinical Development, 15, 257-263.
Fu, X., Chen, W.-C., Argento, C., Clarner, P., Bhatt, V., Dickerson, R., Bou-Assaf, G., Bakhshayeshi, M., Lu, X., Bergelson, S., & Pieracci, J. (2019). Analytical strategies for quantification of adeno-associated virus empty capsids to support process development. Human Gene Therapy Methods, 30, 144-152.
Dickerson, R., Argento, C., Pieracci, J., & Bakhshayeshi, M. (2021). Separating empty and full recombinant adeno-associated virus particles using isocratic anion exchange chromatography. Biotechnology Journal, 16, 2000015.
Sommer, J. M., Smith, P. H., Parthasaranthy, S., Isaacs, J., Vijay, S., Kieran, J., Powell, S. K., McClelland, A., & Wright, J. F. (2003). Quantification of adeno-associated virus particles and empty capsids by optical density measurement. Molecular Therapy, 7, 122-128.
Utturkar, A., Gillette, K., Sun, C.-Y., Pagkaliwangan, M., Quesenberry, R., Schofield, M. (2019). A direct approach for process development using single column experiments results in predictable streamlined multi-column chromatography bioprocesses. Biotechnology Journal, 14(4), https://doi.org/10.1002/biot.201800243.